# ImmunoGenesis to Present IND-Enabling Development Progress and Therapeutic Potential of IMGS-203, a Novel STING Agonist, at SITC 2026 Annual Meeting

- Source: PR Newswire M&A
- Published: 2026-11-04T18:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/immunogenesis-to-present-ind-enabling-development-progress-and-therapeutic-potential-of-imgs-203-a-novel-sting-agonist-at-sitc-2026-annual-meeting-302929630.html
- Canonical: https://groundlevelnews.com/story/immunogenesis-to-present-ind-enabling-development-progress-and-therape-087fc8/

HOUSTON, Nov. 4, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced upcoming presentations describing the IND-enabling activities and therapeutic potential for IMGS-203, the company's novel Stimulator...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._